Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
- Market Cap ₹ 43,488 Cr.
- Current Price ₹ 1,541
- High / Low ₹ 1,831 / 767
- Stock P/E 23.0
- Book Value ₹ 849
- Dividend Yield 0.16 %
- ROCE 9.86 %
- ROE 6.98 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 62.8 days to 43.8 days
Cons
- The company has delivered a poor sales growth of 4.59% over past five years.
- Company has a low return on equity of 8.69% over last 3 years.
- Earnings include an other income of Rs.6,305 Cr.
- Dividend payout has been low at 3.58% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Smallcap 50 BSE 250 LargeMidCap Index Nifty 500 Multicap 50:25:25 Nifty Smallcap 250 BSE 500
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,949 | 2,301 | 5,086 | 6,115 | 7,989 | 5,520 | 6,305 | 6,713 | 7,568 | 8,142 | 8,221 | 7,891 | 8,479 | |
1,617 | 1,805 | 3,618 | 4,349 | 5,089 | 4,417 | 4,977 | 5,407 | 5,676 | 6,453 | 6,748 | 6,649 | 6,756 | |
Operating Profit | 332 | 496 | 1,467 | 1,766 | 2,900 | 1,103 | 1,328 | 1,305 | 1,892 | 1,689 | 1,473 | 1,242 | 1,723 |
OPM % | 17% | 22% | 29% | 29% | 36% | 20% | 21% | 19% | 25% | 21% | 18% | 16% | 20% |
116 | 67 | -86 | 116 | -89 | 326 | 954 | 624 | 469 | 1,044 | 490 | 6,238 | 6,305 | |
Interest | 44 | 31 | 30 | 36 | 153 | 191 | 224 | 256 | 266 | 236 | 207 | 277 | 184 |
Depreciation | 25 | 30 | 119 | 100 | 105 | 96 | 106 | 139 | 151 | 160 | 184 | 202 | 212 |
Profit before tax | 380 | 502 | 1,232 | 1,747 | 2,553 | 1,143 | 1,952 | 1,535 | 1,944 | 2,337 | 1,572 | 7,001 | 7,633 |
Tax % | -2% | 14% | 18% | 15% | 16% | 11% | 17% | 12% | 15% | 15% | 23% | 26% | |
386 | 434 | 1,008 | 1,484 | 2,141 | 1,014 | 1,622 | 1,355 | 1,649 | 1,998 | 1,209 | 5,167 | 5,642 | |
EPS in Rs | 14.25 | 15.99 | 37.14 | 52.60 | 75.86 | 35.95 | 57.49 | 48.01 | 58.46 | 70.80 | 42.84 | 183.12 | 199.95 |
Dividend Payout % | 14% | 12% | 5% | 4% | 3% | 6% | 3% | 5% | 4% | 4% | 6% | 1% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 5% |
3 Years: | 1% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 1% |
3 Years: | -4% |
TTM: | 39% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 35% |
3 Years: | 45% |
1 Year: | 82% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
Reserves | 2,496 | 2,879 | 4,925 | 7,338 | 9,408 | 10,363 | 11,914 | 13,198 | 14,781 | 16,710 | 17,849 | 22,942 | 23,918 |
581 | 353 | 410 | 787 | 2,777 | 2,981 | 3,134 | 3,574 | 3,704 | 3,738 | 3,221 | 707 | 370 | |
782 | 970 | 2,289 | 1,960 | 1,787 | 1,892 | 2,066 | 2,152 | 2,104 | 2,438 | 3,487 | 3,736 | 3,207 | |
Total Liabilities | 3,886 | 4,230 | 7,651 | 10,113 | 14,001 | 15,265 | 17,143 | 18,952 | 20,618 | 22,914 | 24,586 | 27,414 | 27,523 |
276 | 449 | 1,231 | 1,438 | 1,596 | 1,699 | 1,413 | 1,612 | 1,722 | 1,752 | 1,746 | 1,756 | 1,837 | |
CWIP | 172 | 83 | 294 | 276 | 271 | 420 | 286 | 200 | 131 | 109 | 172 | 198 | 170 |
Investments | 1,294 | 1,409 | 1,660 | 1,858 | 1,867 | 3,213 | 3,269 | 4,714 | 6,990 | 8,559 | 10,333 | 12,965 | 15,183 |
2,143 | 2,289 | 4,466 | 6,541 | 10,267 | 9,933 | 12,174 | 12,426 | 11,774 | 12,494 | 12,335 | 12,496 | 10,333 | |
Total Assets | 3,886 | 4,230 | 7,651 | 10,113 | 14,001 | 15,265 | 17,143 | 18,952 | 20,618 | 22,914 | 24,586 | 27,414 | 27,523 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
253 | 114 | 145 | 355 | 878 | 1,124 | 2,490 | 1,579 | 1,243 | 1,216 | 1,474 | -495 | |
-119 | 211 | -176 | -1,545 | -2,580 | -1,137 | -2,256 | -1,607 | -1,235 | -897 | -432 | 3,197 | |
-14 | -385 | -32 | 1,223 | 1,879 | -62 | -155 | -139 | -81 | -305 | -978 | -2,666 | |
Net Cash Flow | 120 | -60 | -64 | 32 | 177 | -75 | 79 | -168 | -73 | 14 | 64 | 35 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 104 | 180 | 175 | 182 | 177 | 253 | 121 | 100 | 120 | 120 | 111 | 115 |
Inventory Days | 128 | 126 | 161 | 182 | 172 | 195 | 141 | 115 | 94 | 100 | 117 | 130 |
Days Payable | 287 | 337 | 343 | 306 | 221 | 273 | 258 | 217 | 201 | 205 | 225 | 307 |
Cash Conversion Cycle | -55 | -31 | -6 | 59 | 129 | 175 | 4 | -3 | 14 | 16 | 3 | -62 |
Working Capital Days | -2 | 98 | 104 | 155 | 179 | 252 | 168 | 130 | 141 | 92 | 52 | 44 |
ROCE % | 15% | 17% | 33% | 26% | 29% | 10% | 13% | 11% | 12% | 11% | 11% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
18 Dec - Glenmark acquires 34% stake in O2 Renewable Energy.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Dec - Glenmark launches Lacosamide Oral Solution, 10 mg/mL.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Dec - IGI presents promising Phase 1 data for ISB 2001.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 27 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
27 Nov - Glenmark launches Travoprost Ophthalmic Solution USP, 0.004%.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Dec 2016TranscriptNotesPPT
-
Jul 2016TranscriptNotesPPT
-
Jan 2016TranscriptNotesPPT
Leadership[1]
<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>